<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30167082</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1949-2553</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>9</Volume>                    <Issue>60</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>03</Day>                    </PubDate>                </JournalIssue>                <Title>Oncotarget</Title>                <ISOAbbreviation>Oncotarget</ISOAbbreviation>            </Journal>            <ArticleTitle>Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications.</ArticleTitle>            <Pagination>                <MedlinePgn>31606-31619</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.25810</ELocationID>            <Abstract>                <AbstractText>The standard of care for breast cancer has gradually evolved from empirical treatments based on clinical-pathological characteristics to the use of targeted approaches based on the molecular profile of the tumor. Consequently, an increasing number of molecularly targeted drugs have been developed. These drugs target specific alterations, called driver mutations, which confer a survival advantage to cancer cells. To date, the main challenge remains the identification of predictive biomarkers for the selection of the optimal treatment. On this basis, we evaluated a panel of 25 genes involved in the mechanisms of targeted treatment resistance, in 16 primary breast cancers and their matched recurrences, developed during treatment. Overall, we found a detection rate of mutations higher than that described in the literature. In particular, the most frequently mutated genes were ERBB2 and those involved in the PI3K/AKT/mTOR and the MAPK signaling pathways. The study revealed substantial discordances between primary tumors and metastases, stressing the need for analysis of metastatic tissues at recurrence. We observed that 85.7% of patients with an early-stage or locally advanced primary tumor showed at least one mutation in the primary tumor. This finding could explain the subsequent relapse and might therefore justify more targeted adjuvant treatments. Finally, the mutations detected in 50% of relapsed tissues could have guided subsequent treatment choices in a different way. This study demonstrates that mutation events may be present at diagnosis or arise during cancer treatment. As a result, profiling primary and metastatic tumor tissues may be a major step in defining optimal treatments.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Toss</LastName>                    <ForeName>Angela</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Piacentini</LastName>                    <ForeName>Federico</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cortesi</LastName>                    <ForeName>Laura</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Artuso</LastName>                    <ForeName>Lucia</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Genome Research, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bernardis</LastName>                    <ForeName>Isabella</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Genome Research, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Parenti</LastName>                    <ForeName>Sandra</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Genome Research, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tenedini</LastName>                    <ForeName>Elena</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Genome Research, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ficarra</LastName>                    <ForeName>Guido</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Maiorana</LastName>                    <ForeName>Antonino</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Iannone</LastName>                    <ForeName>Anna</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Omarini</LastName>                    <ForeName>Claudia</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Moscetti</LastName>                    <ForeName>Luca</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cristofanilli</LastName>                    <ForeName>Massimo</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine-Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="Y">                    <LastName>Federico</LastName>                    <ForeName>Massimo</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Center for Genome Research, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="Y">                    <LastName>Tagliafico</LastName>                    <ForeName>Enrico</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>03</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Oncotarget</MedlineTA>            <NlmUniqueID>101532965</NlmUniqueID>            <ISSNLinking>1949-2553</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2009 Aug 15;15(16):5049-59</RefSource>                <PMID Version="1">19671852</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2012 Feb 9;366(6):520-9</RefSource>                <PMID Version="1">22149876</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2012 Mar 8;366(10):883-892</RefSource>                <PMID Version="1">22397650</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2012 Oct 1;72(19):4875-82</RefSource>                <PMID Version="1">23002210</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2014 Oct 14;4:6611</RefSource>                <PMID Version="1">25312383</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2018 Feb 8;554(7691):189-194</RefSource>                <PMID Version="1">29420467</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2012 Jan;13(1):e43-8</RefSource>                <PMID Version="1">22225725</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2011 Apr 7;472(7341):90-4</RefSource>                <PMID Version="1">21399628</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Treat Rev. 2017 Jan;52:33-40</RefSource>                <PMID Version="1">27886589</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2010 Apr 15;464(7291):999-1005</RefSource>                <PMID Version="1">20393555</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Cycle. 2009 May 1;8(9):1352-8</RefSource>                <PMID Version="1">19305151</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2018 Jan;19(1):87-100</RefSource>                <PMID Version="1">29223745</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Mol Sci. 2017 Jan 04;18(1):</RefSource>                <PMID Version="1">28054957</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Discov. 2013 Feb;3(2):224-37</RefSource>                <PMID Version="1">23220880</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Lett. 2013 Jul;6(1):161-168</RefSource>                <PMID Version="1">23946797</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Treat Rev. 2016 Apr;45:87-96</RefSource>                <PMID Version="1">26995633</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2016 Aug 1;22(15):3755-63</RefSource>                <PMID Version="1">26920887</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Sep 1;34(25):2961-8</RefSource>                <PMID Version="1">27269946</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2014 Sep 15;20(18):4827-36</RefSource>                <PMID Version="1">24987059</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biopreserv Biobank. 2013 Apr;11(2):101-6</RefSource>                <PMID Version="1">24845430</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Jun 20;34(18):2115-24</RefSource>                <PMID Version="1">27091708</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Drugs Today (Barc). 2004 Dec;40(12):991-1002</RefSource>                <PMID Version="1">15645010</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2017 Nov;166(2):339-349</RefSource>                <PMID Version="1">28762010</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2013 Jul 3;105(13):960-7</RefSource>                <PMID Version="1">23739063</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genome Res. 2015 Oct;25(10):1499-507</RefSource>                <PMID Version="1">26430160</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2017 Oct 1;23(19):5687-5695</RefSource>                <PMID Version="1">28679771</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2004;6(5):204-10</RefSource>                <PMID Version="1">15318926</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2017 Jul;18(7):904-916</RefSource>                <PMID Version="1">28576675</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2006 Feb 27;94(4):455-9</RefSource>                <PMID Version="1">16449998</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomed Res Int. 2016;2016:6341870</RefSource>                <PMID Version="1">28127548</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2018 Apr 1;36(10):981-990</RefSource>                <PMID Version="1">29470143</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2015 Apr 23;17:60</RefSource>                <PMID Version="1">25902832</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2012 Oct;23 Suppl 7:vii11-9</RefSource>                <PMID Version="1">22997442</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Oncol. 2016 Oct;10(8):1147-59</RefSource>                <PMID Version="1">27430154</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Onco Targets Ther. 2015 Nov 11;8:3323-8</RefSource>                <PMID Version="1">26648736</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2017 Apr;108(4):671-677</RefSource>                <PMID Version="1">28164408</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Nov 1;31(31):3997-4013</RefSource>                <PMID Version="1">24101045</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2003 Aug;39(12):1668-75</RefSource>                <PMID Version="1">12888360</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2014 Sep 20;32(27):2951-8</RefSource>                <PMID Version="1">25071141</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2017 Jul;16(7):1412-1420</RefSource>                <PMID Version="1">28446639</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">molecular characterization</Keyword>            <Keyword MajorTopicYN="N">next-generation sequencing</Keyword>            <Keyword MajorTopicYN="N">somatic mutations</Keyword>            <Keyword MajorTopicYN="N">treatment resistance</Keyword>        </KeywordList>        <CoiStatement>CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30167082</ArticleId>            <ArticleId IdType="doi">10.18632/oncotarget.25810</ArticleId>            <ArticleId IdType="pii">25810</ArticleId>            <ArticleId IdType="pmc">PMC6114971</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>